JP6216940B2 - ラクダ科動物由来の抗原結合ポリペプチド - Google Patents

ラクダ科動物由来の抗原結合ポリペプチド Download PDF

Info

Publication number
JP6216940B2
JP6216940B2 JP2011515664A JP2011515664A JP6216940B2 JP 6216940 B2 JP6216940 B2 JP 6216940B2 JP 2011515664 A JP2011515664 A JP 2011515664A JP 2011515664 A JP2011515664 A JP 2011515664A JP 6216940 B2 JP6216940 B2 JP 6216940B2
Authority
JP
Japan
Prior art keywords
domain
antigen
encoding
binding polypeptide
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011515664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526493A (ja
JP2011526493A5 (https=
Inventor
ドレイエル トルステン
ドレイエル トルステン
フレデリク ジェロメ ブルアンクヘトト クフリストプヘ
フレデリク ジェロメ ブルアンクヘトト クフリストプヘ
ジョエスプフ ウイルヘルムス デ ハアルド ジョハンネス
ジョエスプフ ウイルヘルムス デ ハアルド ジョハンネス
Original Assignee
アルゲン−エックス ビーブイビーエー
アルゲン−エックス ビーブイビーエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルゲン−エックス ビーブイビーエー, アルゲン−エックス ビーブイビーエー filed Critical アルゲン−エックス ビーブイビーエー
Publication of JP2011526493A publication Critical patent/JP2011526493A/ja
Publication of JP2011526493A5 publication Critical patent/JP2011526493A5/ja
Application granted granted Critical
Publication of JP6216940B2 publication Critical patent/JP6216940B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011515664A 2008-07-02 2009-07-02 ラクダ科動物由来の抗原結合ポリペプチド Active JP6216940B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7773008P 2008-07-02 2008-07-02
GB0812120A GB2461546B (en) 2008-07-02 2008-07-02 Antigen binding polypeptides
GB0812120.4 2008-07-02
US61/077,730 2008-07-02
US11016108P 2008-10-31 2008-10-31
US61/110,161 2008-10-31
PCT/IB2009/006329 WO2010001251A2 (en) 2008-07-02 2009-07-02 Antigen binding polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015250837A Division JP2016128421A (ja) 2008-07-02 2015-12-24 ラクダ科動物由来の抗原結合ポリペプチド

Publications (3)

Publication Number Publication Date
JP2011526493A JP2011526493A (ja) 2011-10-13
JP2011526493A5 JP2011526493A5 (https=) 2012-08-16
JP6216940B2 true JP6216940B2 (ja) 2017-10-25

Family

ID=39707916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011515664A Active JP6216940B2 (ja) 2008-07-02 2009-07-02 ラクダ科動物由来の抗原結合ポリペプチド

Country Status (8)

Country Link
EP (2) EP3061768A1 (https=)
JP (1) JP6216940B2 (https=)
CN (2) CN107739405A (https=)
AU (1) AU2009265278B2 (https=)
CA (1) CA2728076C (https=)
DK (1) DK2310413T3 (https=)
GB (1) GB2461546B (https=)
WO (1) WO2010001251A2 (https=)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CN114805583A (zh) 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体
SI2621531T1 (sl) 2010-09-27 2017-06-30 Morphosys Ag Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl
EP2635602B1 (en) 2010-11-03 2016-09-07 Argen-X Nv Anti c-met antibodies
CN103620405B (zh) * 2010-12-31 2016-05-25 生物蛋白有限公司 全面单克隆抗体产生
DK2686347T3 (en) * 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
CA2832389A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
JP6177231B2 (ja) 2011-04-20 2017-08-09 ゲンマブ エー／エス Ｈｅｒ２に対する二重特異性抗体
EP2699260B1 (en) 2011-04-20 2024-11-20 Genmab A/S Bispecifc antibodies against her2
US10344050B2 (en) 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
IN2015DN00140A (https=) * 2012-08-31 2015-06-12 Argen X Bv
IN2015DN00138A (https=) * 2012-08-31 2015-06-12 Argen X Bv
PL2968440T3 (pl) 2013-03-15 2019-12-31 Zymeworks Inc. Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
WO2015015003A1 (en) 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
TWI707038B (zh) 2013-08-05 2020-10-11 美商扭轉生物科技有限公司 重新合成之基因庫
ES2698976T3 (es) 2013-11-04 2019-02-06 Inst Nat Sante Rech Med Anticuerpo sintético de un solo dominio
RU2729194C2 (ru) 2013-12-27 2020-08-05 Займворкс Инк. Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
AU2015318556C1 (en) 2014-09-17 2021-01-07 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
KR20180050411A (ko) 2015-09-18 2018-05-14 트위스트 바이오사이언스 코포레이션 올리고핵산 변이체 라이브러리 및 그의 합성
KR102794025B1 (ko) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
AU2017292184A1 (en) 2016-07-08 2019-02-07 Staten Biotechnology B.V. Anti-Apoc3 antibodies and methods of use thereof
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
WO2018103093A1 (zh) * 2016-12-09 2018-06-14 深圳华大基因研究院 骆驼科抗体可变区免疫组库构建的引物组合及应用
CN110892485B (zh) 2017-02-22 2024-03-22 特韦斯特生物科学公司 基于核酸的数据存储
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
GB201707484D0 (en) 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
US10696965B2 (en) 2017-06-12 2020-06-30 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
CN111566125A (zh) 2017-09-11 2020-08-21 特韦斯特生物科学公司 Gpcr结合蛋白及其合成
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
KR20200074975A (ko) 2017-10-31 2020-06-25 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
KR102804057B1 (ko) 2018-01-04 2025-05-07 트위스트 바이오사이언스 코포레이션 Dna 기반 디지털 정보 저장
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
CN109206511B (zh) * 2018-09-13 2021-03-16 东南大学 能够特异结合HPVl6-E6蛋白的纳米抗体及其编码序列、制备方法和应用
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
US12357959B2 (en) 2018-12-26 2025-07-15 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
CN113766930B (zh) 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
CA3131691A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
CN114126646B (zh) * 2019-02-27 2025-05-30 浙江纳米抗体技术中心有限公司 基于序列的高通量方法产生骆驼抗体以高分辨率覆盖广泛表位
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
JP2022548309A (ja) 2019-09-23 2022-11-17 ツイスト バイオサイエンス コーポレーション Ｃｒｔｈ２のバリアント核酸ライブラリー
WO2021061842A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
CN110642948B (zh) * 2019-10-09 2021-06-29 达石药业(广东)有限公司 B7-h3纳米抗体、其制备方法及用途
IL293670A (en) 2019-12-09 2022-08-01 Twist Bioscience Corp Variable nucleic acid libraries for adenosine receptors
JP7651477B2 (ja) * 2019-12-27 2025-03-26 株式会社カネカ プライマーセット及びそれを用いて標的核酸を検出する方法
GB202003444D0 (en) 2020-03-10 2020-04-22 argenx BV Musk agonist antibody
CN116284373B (zh) * 2020-08-14 2026-04-14 上海洛启生物医药技术有限公司 非pH依赖性长效型抗血清白蛋白纳米抗体及其应用
CN114591436B (zh) * 2020-12-07 2022-12-02 生物岛实验室 胃蛋白酶原i的特异性抗体及其制备方法与应用
JP2024522213A (ja) 2021-06-14 2024-06-11 アルジェニクス ビーブイ 抗ｉｌ－９抗体及びその使用方法
KR20240133723A (ko) 2022-01-18 2024-09-04 아르제넥스 비브이 Fab 단편의 분무화
IL314367A (en) 2022-01-18 2024-09-01 argenx BV Antibodies to galectin 10
GB202203269D0 (en) 2022-03-09 2022-04-20 Argenx Iip Bv TGF-Beta antibodies
TW202504921A (zh) * 2023-02-28 2025-02-01 中國大陸商禮新醫藥科技（上海）有限公司 Ceacam5依賴性4-1bb促效性雙特異性抗體
KR20250155032A (ko) 2023-02-28 2025-10-29 라노바 메디신즈 리미티드 Ceacam5 의존적 4-1bb-작용성 이중특이적 항체
CN117310163B (zh) * 2023-11-23 2024-02-13 北京贝思泰生物科技有限公司 一种基于重组抗体的呼吸道合胞病毒检测方法
CN117986360B (zh) * 2024-02-01 2024-08-27 生物岛实验室 Il18蛋白的特异性抗体及其制备方法与应用
CN119591719B (zh) * 2024-11-25 2025-10-21 江苏集萃崛创生物科技研究所有限公司 靶向fap的纳米抗体、car-t细胞及其应用
CN119708213B (zh) * 2024-12-25 2025-12-12 河北科技师范学院 针对猪流行性腹泻病毒的纳米抗体或抗原结合片段及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU701578B2 (en) * 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
GB9926084D0 (en) * 1999-11-03 2000-01-12 King S College London Recombinant fusion molecules
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DE60238497D1 (de) * 2001-09-14 2011-01-13 Fraunhofer Ges Forschung Immunglobulin mit einem bestimmten rahmengerüst und verfahren zu dessen herstellung und verwendung
ES2852423T3 (es) * 2005-05-20 2021-09-13 Ablynx Nv NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
US20070269442A1 (en) * 2006-05-19 2007-11-22 Robert J. Webber Chimeric monoclonal antibody recognizing iNOS
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
BRPI0718118A2 (pt) * 2006-10-27 2017-05-30 Lpath Inc composições e métodos para ligação de sphingosine-1-fosfato
WO2008070367A2 (en) * 2006-11-01 2008-06-12 Facet Biotech Corporation Mammalian cell-based immunoglobulin display libraries
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies

Also Published As

Publication number Publication date
WO2010001251A2 (en) 2010-01-07
EP3061768A1 (en) 2016-08-31
CN107739405A (zh) 2018-02-27
GB0812120D0 (en) 2008-08-06
WO2010001251A3 (en) 2010-03-11
CN102216328A (zh) 2011-10-12
CA2728076A1 (en) 2010-01-07
GB2461546B (en) 2010-07-07
EP2310413B1 (en) 2017-03-01
JP2011526493A (ja) 2011-10-13
CA2728076C (en) 2020-05-19
DK2310413T3 (en) 2017-06-06
AU2009265278A1 (en) 2010-01-07
EP2310413A2 (en) 2011-04-20
AU2009265278B2 (en) 2015-03-19
GB2461546A (en) 2010-01-06

Similar Documents

Publication Publication Date Title
JP6216940B2 (ja) ラクダ科動物由来の抗原結合ポリペプチド
US9221918B2 (en) Antigen binding polypeptides
JP6250284B2 (ja) ヒト化抗体
JP2015524404A (ja) 高度に保存された標的に対するラクダ科動物由来の配列を含む抗体
JP2018064561A (ja) ラクダ科動物由来の抗原結合ポリペプチド
WO2023161448A1 (en) Human-like target-binding proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160205

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160302

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160506

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170425

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170829

R150 Certificate of patent or registration of utility model

Ref document number: 6216940

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250